

Jun Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3012429/publications.pdf>

Version: 2024-02-01

18
papers

6,040
citations

623734

14
h-index

839539

18
g-index

28
all docs

28
docs citations

28
times ranked

11156
citing authors

#	ARTICLE	IF	CITATIONS
1	A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. <i>Science</i> , 2020, 369, 650-655.	12.6	1,292
2	Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet</i> , The, 2020, 396, 479-488.	13.7	1,011
3	Distinct conformational states of SARS-CoV-2 spike protein. <i>Science</i> , 2020, 369, 1586-1592.	12.6	995
4	CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 283.	17.1	806
5	Structural impact on SARS-CoV-2 spike protein by D614G substitution. <i>Science</i> , 2021, 372, 525-530.	12.6	344
6	Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant. <i>Science</i> , 2021, 374, 1353-1360.	12.6	246
7	A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. <i>Nature Communications</i> , 2020, 11, 4081.	12.8	220
8	Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 642-648.	12.6	211
9	HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry. <i>Nature Metabolism</i> , 2020, 2, 1391-1400.	11.9	207
10	Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1654-1664.	9.1	200
11	Structure of SARS-CoV-2 spike protein. <i>Current Opinion in Virology</i> , 2021, 50, 173-182.	5.4	122
12	A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 202-209.	8.2	110
13	Structural and functional impact by SARS-CoV-2 Omicron spike mutations. <i>Cell Reports</i> , 2022, 39, 110729.	6.4	102
14	CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 347.	17.1	64
15	Cross-species tropism and antigenic landscapes of circulating SARS-CoV-2 variants. <i>Cell Reports</i> , 2022, 38, 110558.	6.4	15
16	Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 139.	17.1	14
17	RBD206-sc-dimer induced robust cross-neutralization against SARS-CoV-2 and variants of concern. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 390.	17.1	5
18	Fighting SARS-CoV-2 with structural biology methods. <i>Nature Methods</i> , 2022, 19, 381-383.	19.0	3